Development of a Novel Inhibitory Chimeric Anti-HER2 Monoclonal Antibody.

CONCLUSION: The c2A8 mAb is potentially a valuable tool for targeted immunotherapy of HER2 positive cancers. PMID: 30864553 [PubMed - in process]
Source: Iranian Journal of Immunology - Category: Allergy & Immunology Tags: Iran J Immunol Source Type: research